{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T05:16:16Z","timestamp":1777785376352,"version":"3.51.4"},"reference-count":38,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T00:00:00Z","timestamp":1568160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Am Psychiatr Nurses Assoc"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:p>INTRODUCTION: Prolonged QT interval (PQTI) is a cardiac condition widely documented in the mental health literature and linked to psychotropic medication use. Medications notable for contributing to the condition are antipsychotics, antidepressants, and some mood stabilizers. Although additional medication classes and other contributing risk factors are often present, the prudent mental health provider benefits from having a basic understanding of this condition and how to prevent and manage it with safe prescribing practices. AIMS: This guide seeks to provide mental health prescribers with a basic understanding of the risk factors, pathophysiology, identification, and management of PQTI. METHOD: Relevant literature and practice guidelines were reviewed and summarized with a focus on practical interventions for the psychiatric mental health nurse practitioner (PMHNP). RESULTS: One of the primary contributing factors to PQTI development and complications is polypharmacy. Patients with co-occurring medical, mental health, and\/or substance use disorders may receive medications from multiple providers. Anticancer drugs, antiarrhythmic medications, and even a number of common antibiotics can increase the QT interval, making it a challenge for even the most experienced mental health provider to monitor medication interactions and side effects that contribute to PQTI. Having a sound knowledge base of these factors can guide safe PMHNP practice. CONCLUSIONS: Decision-making trees grounded in evidence-based research were developed in order to direct thorough assessment and safe treatment of patients requiring psychotropic medications.<\/jats:p>","DOI":"10.1177\/1078390319873049","type":"journal-article","created":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T09:06:35Z","timestamp":1568192795000},"page":"344-353","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Prolonged QT Interval in Patients Receiving Psychotropic Medications"],"prefix":"10.1177","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1371-7081","authenticated-orcid":false,"given":"Rebecca S.","family":"Swenson","sequence":"first","affiliation":[{"name":"Rebecca S. Swenson, FNP-BC, APNP, University of Wisconsin\u2013Madison, WI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Murphy-Ende","sequence":"additional","affiliation":[{"name":"Kathleen Murphy-Ende, PhD, PsyD, PMHNP-BC, University of Wisconsin\u2013Madison, WI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,9,11]]},"reference":[{"key":"bibr1-1078390319873049","unstructured":"Centers for Disease Control and Prevention. (2017, November 28). Heart facts. Retrieved from https:\/\/www.cdc.gov\/heartdisease\/facts.htm"},{"key":"bibr2-1078390319873049","unstructured":"CredibleMeds. (2018). Risk categories for drugs that prolong QT & induce Torsades de Pointes (TdP). Retrieved from http:\/\/crediblemeds.org\/index.php\/new-drug-list"},{"key":"bibr3-1078390319873049","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e31820bf86e"},{"key":"bibr4-1078390319873049","unstructured":"Epocrates. (2018). The #1 medical reference app. Retrieved from https:\/\/www.epocrates.com\/"},{"key":"bibr5-1078390319873049","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.04.035"},{"key":"bibr6-1078390319873049","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8167.2006.00408.x"},{"key":"bibr7-1078390319873049","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-017-2381-5"},{"key":"bibr8-1078390319873049","unstructured":"Herndon C., Lider J. M., Daniels A. M. (2015, December). QT intervals and antidepressants. Retrieved from https:\/\/www.practicalpainmanagement.com\/treatments\/pharmacological\/non-opioids\/qt-intervals-antidepressants"},{"key":"bibr9-1078390319873049","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/5023954"},{"key":"bibr10-1078390319873049","doi-asserted-by":"publisher","DOI":"10.1136\/bjsm.2008.054734"},{"key":"bibr11-1078390319873049","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.863076"},{"key":"bibr12-1078390319873049","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60733-3"},{"key":"bibr13-1078390319873049","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.75.8.591"},{"key":"bibr14-1078390319873049","unstructured":"Lexicomp. (2018). Retrieved from https:\/\/www.wolterskluwercdi.com\/"},{"key":"bibr15-1078390319873049","doi-asserted-by":"publisher","DOI":"10.1016\/j.jelectrocard.2006.09.003"},{"key":"bibr16-1078390319873049","volume-title":"Psychiatric update 2018: Solving clinical challenges, improving patient care","author":"McCarron R. M.","year":"2018"},{"key":"bibr17-1078390319873049","unstructured":"Medi-cal (2017, August 31). Clinical review: Drug-induced QT interval prolongation. Retrieved from https:\/\/files.medi-cal.ca.gov\/pubsdoco\/dur\/Articles\/dured_26204.pdf"},{"key":"bibr18-1078390319873049","unstructured":"Medsafe. (2010, December). New Zealand Medicines and Medical Devices Safety Authority. Retrieved from http:\/\/www.medsafe.govt.nz\/profs\/PUArticles\/DrugInducedQTProlongation.htm"},{"key":"bibr19-1078390319873049","doi-asserted-by":"publisher","DOI":"10.1177\/2045125317721662"},{"key":"bibr20-1078390319873049","doi-asserted-by":"publisher","DOI":"10.1002\/jhm.691"},{"key":"bibr21-1078390319873049","unstructured":"Mitchell L. B. (2017, September). Long QT syndrome and torsades de pointes ventricular tachycardia. Retrieved from https:\/\/www.merckmanuals.com\/professional\/cardiovascular-disorders\/arrhythmias-and-conduction-disorders\/long-qt-syndrome-and-torsades-de-pointes-ventricular-tachycardia"},{"key":"bibr22-1078390319873049","unstructured":"Moses S. (2017, March 2). Prolonged QT interval due to medication. Retrieved from https:\/\/fpnotebook.com\/legacy\/CV\/Pharm\/PrlngdQtIntrvlDTMdctn.htm"},{"key":"bibr23-1078390319873049","doi-asserted-by":"publisher","DOI":"10.1177\/2042098612454283"},{"key":"bibr24-1078390319873049","unstructured":"NHS Greater Glasgow & Clyde Medicines Information Services. (2012, December). Drug induced QT prolongation. Retrieved from http:\/\/www.ggcprescribing.org.uk\/media\/uploads\/ps_extra\/medicines_update_extra_qt_prolongation_may_15_incl_hydroxyzine.pdf"},{"key":"bibr25-1078390319873049","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-003-0522-z"},{"key":"bibr26-1078390319873049","doi-asserted-by":"publisher","DOI":"10.1046\/j.1540-8167.2002.01211.x"},{"key":"bibr27-1078390319873049","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.05.046"},{"key":"bibr28-1078390319873049","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806994"},{"key":"bibr29-1078390319873049","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.863209"},{"key":"bibr30-1078390319873049","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.08.067"},{"key":"bibr31-1078390319873049","volume-title":"Advanced practice psychiatric nursing","author":"Tusaie K. R.","year":"2017"},{"key":"bibr32-1078390319873049","volume-title":"Guidance for industry: E14 Clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs","author":"U.S. Department of Health &amp; Human Services","year":"2005"},{"key":"bibr33-1078390319873049","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13740"},{"key":"bibr34-1078390319873049","doi-asserted-by":"publisher","DOI":"10.2165\/11318880-000000000-00000"},{"key":"bibr35-1078390319873049","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2005.02.011"},{"key":"bibr36-1078390319873049","doi-asserted-by":"publisher","DOI":"10.1007\/s40596-017-0738-9"},{"key":"bibr37-1078390319873049","unstructured":"Wisconsin Department of Health Services (2018). Informed consent for medications F-24277 series: psychotropic medications. Retrieved from https:\/\/www.dhs.wisconsin.gov\/forms\/medbrandname.htm"},{"key":"bibr38-1078390319873049","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5273(02)00248-6"}],"container-title":["Journal of the American Psychiatric Nurses Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078390319873049","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078390319873049","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078390319873049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:43:49Z","timestamp":1777491829000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078390319873049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,11]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1177\/1078390319873049"],"URL":"https:\/\/doi.org\/10.1177\/1078390319873049","relation":{},"ISSN":["1078-3903","1532-5725"],"issn-type":[{"value":"1078-3903","type":"print"},{"value":"1532-5725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,11]]}}}